Bright Minds Biosciences Inc.
DRUGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. With a market capitalization of $746.9M, it sits in small-cap territory. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Market Cap
$746.9M
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
-8.84
EPS (TTM)
$-2.46
EPS (Fwd)
$-8.61
ROE
-15.0%
ROA
-10.4%
Cash
$309.7M
Total Debt
$82,130
Free CF
-$13.1M
52W Change
191.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $309.7M in cash comfortably exceeding the $82K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$13.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -15.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
DRUG's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bright Minds Biosciences Inc. and its sector.